Skip to main content
TipRanks
Go Ultimate75% OFF

Transgene (TGNA) AI Stock Analysis

0 Followers
DE:TGNA

Transgene

(Frankfurt:TGNA)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Low LeverageVery low leverage and a sizable equity base provide financial capacity relative to debt, reducing balance-sheet strain while the company advances its oncology pipeline. This is a meaningful buffer, although it does not eliminate the need to fund ongoing losses.
Negative Factors
Revenue CollapseRevenue falling about 96% to roughly 0.14M in 2025 shows that current commercial inflows are highly unstable. Such volatility makes planning and self-funding difficult, increases dependence on successful pipeline milestones, and weakens confidence in a durable revenue base.

Transgene (TGNA) vs. iShares MSCI Germany ETF (EWG)

-60%-50%-40%-30%-20%-10%0%10%20%DE:TGNA-44.60%EWG+7.62%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 101.81M
Dividend Yield
―
Average Volume (3M)
1,055
Price to Earnings (P/E)
-4.2
Beta (1Y)
-0.10
Revenue Growth
189.81%
EPS Growth
38.50%
Country
Germany
Employees
152
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Transgene Business Overview & Revenue Model

Company Description

Transgene SA, a French biotechnology firm headquartered in Illkirch-Graffenstaden, specializes in designing and developing groundbreaking therapeutic vaccines and oncolytic viruses to combat cancer and infectious diseases. Founded in 1979 and operati...

Transgene Earnings Call Summary

Earnings Call Date:Mar 24, 2026(Q4-2025)|% Change Since:-2.69%|Next Earnings Date:May 13, 2019
Earnings Call SentimentPositive

The call emphasized several strong positives: robust fundraising (EUR 105M), a strengthened balance sheet (EUR 39M debt conversion), compelling Phase I efficacy and durable immunogenicity signals for TG4050 (100% disease-free in treated Phase I patients; 73% immunogenicity with responses persisting 24 months), encouraging BT-001 combination data, and a clear plan for manufacturing and regulatory readiness. Counterbalancing these highlights are timing and operational risks (GMP readiness targeted Q3 2027), immature/pending pivotal readouts (Phase II 2-year DFS not yet available), ongoing cash burn (~EUR 38.2M in 2025) and some dependence on broader field validation. Overall, the positive clinical signals and strengthened financial position outweigh the execution and timing risks at this stage.

Positive Updates

Successful Fundraising and Balance Sheet Strengthening
Raised approximately EUR 105 million in December 2025 and converted EUR 39 million of debt into equity, leaving the company virtually debt-free and providing financial visibility/runway through early 2028.

Negative Updates

Key Efficacy Readouts Not Yet Mature or Fully Peer-Reviewed
Primary efficacy readout for Phase I/II (2-year DFS for Phase II) is pending until patients reach 2 years post-randomization; Phase I comprehensive analysis is currently a preprint under peer review, so data are not yet fully validated by peer-reviewed publication.

Company Guidance

The call laid out clear, metric-driven guidance: Transgene raised ~EUR 105m in December 2025 and converted ~EUR 39m of debt to equity (now virtually debt‑free), giving cash visibility through early 2028 (first quarter 2028) after a 2025 cash burn of ~EUR 38.2m; clinically, the primary endpoint for the randomized Phase I/II TG4050 study is 2‑year disease‑free survival (DFS) with an efficacy readout once all patients reach 2 years, Phase I 3‑year DFS data expected Q2–Q3 2026 and 4‑year follow‑up Q2–Q3 2027, Phase II patient randomization to be completed by Q2 2026 and first Phase II immunogenicity data in H2 2026 (with ~1 year follow‑up possible), and Phase I translational results showed 100% DFS at ≥2 years in treated HPV‑negative HNSCC patients vs. 3 relapses in controls and neoantigen‑specific T‑cell responses in 73% of evaluable patients that persisted 24 months; manufacturing and regulatory investments target full GMP capacity by Q3 2027 and a second Phase I indication is slated to start in 2026.

Transgene Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:TGNA against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
FR:IPHFR:IPH50NeutralEUR 110.36M-1.94152.56%―-29.48%7.91%
FR:NANOFR:NANO47NeutralEUR 1.26B-21.8989.71%―――
FR:ALCLSFR:ALCLS46NeutralEUR 71.53M-0.85-319.92%―-5.98%-8.67%
FR:OSEFR:OSE43NeutralEUR 34.33M-0.86-96.73%―-96.25%-197.89%
FR:MAATFR:MAAT28UnderperformEUR 16.97M-0.47――-19.02%10.39%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%150%DE:TGNAFR:IPHFR:NANOFR:OSEFR:ALCLSFR:MAATDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:TGNA and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:TGNATransgene SA0.69-0.58-45.91%
FR:IPHInnate Pharma S.A.0.99-0.62-38.40%
FR:NANONanobiotix SA24.085.8432.02%
FR:OSEOSE Immunotherapeutics1.46-3.95-73.01%
FR:ALCLSCellectis SA0.99-3.31-77.00%
FR:MAATMaaT Pharma0.90-3.26-78.37%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.